- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Idaho, CMS Talk Again; Drug Pricing Poll Answers Vary; Senators Want 340B Info
Idaho is still seeking a way to get its state's health insurance plans approved by CMS; a new poll finds that support for action on drug pricing dips when potential ramifications are weighed; senators seek information on hospitals' use of 340B drug discounts.
Idaho Still Seeking Way to Get State's Health Plan Approved
Idaho insurance head Dean Cameron and Sen. Jim Risch, R-Idaho, met with CMS chief Seema Verma in Washington this week to see if there is still a way around the state’s controversial plan to skirt Affordable Care Act (ACA) rules, The Hill reported. The Trump administration has blocked the plan, saying that it contained measures that violated the ACA, such as allowing people with pre-existing conditions to be charged more. Cameron said that perhaps a discount might be given to healthy people instead.
Polls Finds Support for Drug Pricing Action Dips When Ramifications Considered
A POLITICO—Harvard T.H. Chan School of Public Health poll finds bipartisan support for the idea of drastic government action on drug prices. Nine out of 10 favor giving Medicare the power to negotiate directly with pharmaceutical manufacturers, but that support falters when Americans face possible negative trade-offs, Politico reported. Support fell to 42% when respondents weighed the risk that some drug companies might respond by halting the sale of certain drugs to seniors. And although 80% favored limiting the price of drugs sold to state health programs, only 38% still liked the idea if it meant less research and development.
Senators Want Information on Hospitals' Use of 340B Drug Discounts
Senators moved closer to joining the House of Representatives to push hospitals to report how they use 340B drug discounts, Modern Healthcare reported. Senate Health, Education, Labor and Pensions Committee Chairman Lamar Alexander, R-Tennessee, said he wants to know where hospitals and clinics are applying the drug discounts, how much of the discounts go to patients, and which kinds of programs the providers are funding for patients with the money that isn't directly passed on. It’s the first time senators have gotten involved in the lobbying dispute between the pharmaceutical industry and hospitals.
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
What We’re Reading: Affordable Home Care; Mycoplasma Infections Rise; Opioid Crisis Settlement
December 4th 2023Families struggle to find affordable, reliable home health aides; reports of increased pediatric pneumonia cases; legal battle ensues over Purdue Pharma’s bankruptcy settlement.
Read More
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen
New Data Update Myasthenia Gravis Outcomes for Patients in Australia
December 3rd 2023Patients living with myasthenia gravis in Australia were surveyed their demographic information, clinical features of the autoimmune disease, adverse effects from treatment, and quality of life. Outcomes were compared against 2011 data from Australia and 2019 data from the United States.
Read More
NK Cell Therapy SNK01 Improves Cognitive Function in Alzheimer Disease for up to 11 Weeks
December 3rd 2023Among 10 patients evaluated, compared with their baseline at 1 week after receiving their final dose in the trial, 30% demonstrated clinical improvement on the Alzheimer’s disease composite score.
Read More
